Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 1 | Arthritis Research & Therapy

Figure 1

From: Synovial membrane immunohistology in early-untreated rheumatoid arthritis reveals high expression of catabolic bone markers that is modulated by methotrexate

Figure 1

Methotrexate decreases lymphocyte and macrophage infiltration in the rheumatoid synovium of early-untreated rheumatoid arthritis. Brown immunohistochemistry (diaminobenzidine) staining of cell surface markers in synovial biopsies of early rheumatoid arthritis (RA). Synovial CD3 expression in early-untreated RA synovium (A) decreased significantly following 8 weeks of methotrexate (MTX) treatment (B). Synovial CD68 expression in early, untreated RA synovium (D) decreased significantly following 8 weeks of MTX treatment (E). Synovial CD31 expression in early, untreated RA (G) is not changed following 8 weeks of MTX treatment (H). Results from the semi-quantitative double-blind analysis of synovial CD3 (C), CD68 (F) and CD31 (I) expression before and 8 weeks after MTX treatment. *p<0.05.

Back to article page